How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, sex, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about durvalumab with tremelimumab

Marketing authorisation indication

2.1

Durvalumab (Imfinzi, AstraZeneca) in combination with tremelimumab (Imjudo, AstraZeneca) is indicated 'for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC)'.

Price

2.3

The list price of durvalumab is £592.00 per 2.4-ml vial and £2,466.00 per 10-ml vial (excluding VAT; BNF online, accessed January 2025). The list price of tremelimumab is £20,610.00 per 15-ml vial (excluding VAT; BNF online, accessed January 2025).

2.4

The company has a commercial arrangement. This makes durvalumab with tremelimumab available to the NHS with a discount. The size of the discount is commercial in confidence.